secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117193
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q3 net loss $23.2M; FDA tentative approval for YUTREPIA; raised $100M
------------------------------------------------------------------------------

- Net loss of $23.2M ($0.30/diluted share) vs $15.8M loss a year ago; revenue $4.4M from Treprostinil injection promotion.
- Cash $204.4M as of Sep 30, 2024, boosted by $67.5M public offering and $32.5M from HCRx RIFA amendment.
- FDA granted tentative approval for YUTREPIA (treprostinil inhalation powder) for PAH and PH-ILD; final approval delayed until May 23, 2025.
- Supreme Court rejected UTHR appeal on '793 patent; remaining '327 patent trial set for June 2025; Liquidia sued FDA over exclusivity.
- Expanded Pharmosa collaboration for L606 to Europe, Japan; $3.5M upfront, up to $157.75M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/0001104659-24-117193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/tm2428261d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer